A Retrospective Review - Anti-HLA Antibodies

NCT00460824 | Withdrawn

• 1 other identifier: IRB00003541
• Study Type: observational
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

Transplant rejection following organ transplant occurs because the recipient's immune system attacks the transplanted organ. The recipients immune system recognizes the transplanted organ as foreign tissue and attempts to destroy it in the similar way that it attempts to destroy infectious agents such as bacteria and viruses. The human leukocyte antigen (HLA) system is a set of genes that is responsible for controlling an individuals' ability to tell the difference between an infectious agent and self tissue. Differences in HLA genes between donors and recipients play a major part in influencing the rejection or acceptance of foreign tissue (i.e. transplanted organs). Due to time limitations in heart transplantation, HLA matching is not considered. It is unclear how individual HLA differences affect the recovery and expected lifespan of pediatric heart transplant recipients. This study is designed to look at the donor-recipient matching and mismatching to determine if mismatching leads to more complications, shorter graft survival and, therefore, increased risk of death following pediatric heart transplantation.

Conditions

Congenital Disorders

Keywords

transplant; HLA antibodies matching; immunologic mismatching

Eligibility Criteria

• Age: Up to 18 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64)
• Sampling Method: Non-Probability Sample

Study Population

* heart transplants at Childrens Healthcare of Atlanta, Egleston Hospital * transplants between July 1, 1988 through and including January 31, 2007 * complete HLA data * survived more than 30 days after transplant

You may qualify if:

• heart transplants at Childrens Healthcare of Atlanta, Egleston Hospital
• transplants between July 1, 1988 through and including January 31, 2007
• complete HLA data
• survived more than 30 days after transplant

You may not qualify if:

• subjects undergoing retransplant

Sponsors & Collaborators

• Emory University: lead

Study Sites (1)

Emory University

Atlanta, Georgia, 30322, United States

Location

MeSH Terms

Conditions

Congenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

• Robert Bray, PhD

  Emory University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor

Study Record Dates

• First Submitted: April 16, 2007
• First Posted: April 17, 2007
• Study Start: July 1, 1988
• Last Updated: December 31, 2013

Record last verified: 2013-12

Locations

US (1)